Actively Recruiting
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals
Led by Haukeland University Hospital · Updated on 2025-09-15
16
Participants Needed
1
Research Sites
33 weeks
Total Duration
On this page
Sponsors
H
Haukeland University Hospital
Lead Sponsor
U
University of Bergen
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. Participants will receive either NAD supplementation or a placebo and their sleep will be measured to detect any differences between the two groups.
CONDITIONS
Official Title
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent.
- Male or female.
- Participants who are healthy as determined by medical evaluation including medical history and physical examination.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol.
- Self-reported normal sleep patterns, assessed by Pittsburgh sleep quality index (PSQI; cutoff 5 5).
- No current use of sleep medications or supplements.
- Able to wear polysomnographic equipment and actigraphy during nighttime.
You will not qualify if you...
- History of sleep disorders (e.g. insomnia, sleep apnea).
- Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) �b5 5), sleep related movement disorders (periodic limb movement index (PLMI) �b5 15, and parasomnias (like REM sleep behavior disorder (RBD)).
- Chronic use of alcohol, tobacco, or medications affecting sleep.
- Significant psychiatric or medical conditions (including neurological, heart, lung, or sleep disorders/diseases).
- Travelled >1 time zone and night work <1 month before study, or during the study.
- Extreme chronotype according to the Composite Morningness Questionnaire (evening type; <22 and morning type >44).
- Pregnancy.
- Breastfeeding.
- Supplements resulting in > 20 mg daily of nicotinamide riboside, nicotinamide mononucleotide (NMN), niacin (vitamin B3, nicotinic acid amide or other vitamin B3 analogues) less than 3 months prior to randomization.
- Participation in other clinical trials last 3 months.
- Deemed ineligible by lead principal investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Haukeland University Hospital
Bergen, Norway
Actively Recruiting
Research Team
C
Charalampos Tzoulis, PhD
CONTACT
K
Katarina Lundervold, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here